Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSIBBBOOST
2025-523033-26-00Phase 2Authorised
- Sponsor
- Maastricht University Medical Center+
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib and febuxostat in non-small cell lung cancer (NSCLC), sponsored by Maastricht University Medical Center+. Primary endpoint: Osimertinib concentration in CSF and plasma before and after combination with febuxostat. Planned start Mar 2026; status: authorised.
02
Drugs
osimertinibfebuxostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-523033-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523033-26-00.